General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.
1. Opening Hook
The June call almost didn’t happen. The 2nd June session was cancelled after a medical emergency involving Chairman Atul Modi, and the whole thing shifted to 29th June with CFO Namrata Modi chairing in his place. A dental-materials company that sells calm and hygiene opened its year-end call recovering from a scare of its own.
The numbers arrived steady. Full-year revenue climbed to roughly ₹72 crore, net profit to about ₹21 crore, and the balance sheet still carries zero debt. Then the fourth quarter walked in and sales barely moved — up under 2%.
A firm exporting to more than 90 countries spent the year explaining wars, tariffs and shipping. The profit held. The stock, over twelve months, did the opposite. That gap is the story.
2. At a Glance
- FY26 revenue ~₹72 Cr (up ~14%) – Growth arrived; it just checked its passport at every border first.
- Q4 sales up under 2% – The quarter that management called “more challenging” declined to grow much, in fairness to the label.
- Net profit ~₹21 Cr, OPM 35.6% – Margins stayed thick while the top line thinned. A company that would rather earn well than sell fast.
- Zero debt, current ratio 14.8 – The balance sheet is so clean it squeaks.
- Inventory days 235, up from 208 – Stock that sits for two-thirds of a year, waiting for a war to end.
- Dividend payout 0% – Down from 7% a year earlier. The cash stayed home.
- Stock down 30.7% over one year – The market read the same results and priced a different mood.
3. Management’s Key Commentary
Management leaned on adjectives all afternoon. Here are the verbatim highlights, decoded.
“Financial year 2025-’26 was a year of steady growth, disciplined execution and continued strategic progress.” → (Three virtues, zero verbs. The sentence works whether revenue rose 14% or 4%.)
“We successfully mitigated inflationary pressures while maintaining healthy profitability.” → (Costs went up; margins didn’t. Somebody in procurement earned their tea.)
“Looking ahead, we remain optimistic about the opportunities before us while continuing to remain prudent in light of global uncertainty.” → (“Optimistic” and “prudent” in one breath — the corporate equivalent of a foot on both pedals.)
“[The UAE subsidiary] we have opened in the month of February and only. So, in March, this crisis happened.” — Namrata Modi → (One month of operations before the region interrupted. The launch and the war shared a calendar.)
“We don’t have the exact number yet. I will pass on the exact number to you.” — Dr. Sai Kalyan, on R&D spend → (Asked what share of revenue funds research, the Director of Research fielded it with a promissory note.)
“Everyone is at the same level. Probably we are slightly ahead than the other MNCs.” — Dr. Sai Kalyan, on digital dentistry → (The pitch versus Ivoclar and Dentsply rests on a “probably” and a “slightly.” Confidence, rationed.)
“There’s a small drop of just 2%. So, we will compensate this loss this year.”
